Encompass Health stock reports 9.6 percent revenue growth

Published on 10/07/2026 at 00:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Encompass Health stock posted adjusted EPS of USD 1.55 in Q2 2026, beating consensus by USD 0.07. Third quarter results are scheduled for October 28, 2026.

EHC, US29261A1007, Illustration mit AI erstellt.

Encompass Health stock reported 9.6 percent revenue growth in the second quarter of 2026, while its NYSE price was last at USD 124.69 on October 6, 2026, at 4:00 p.m. ET, up 3.08 percent from the prior close. The combination gives investors two immediate reference points: operating growth and a share price near the upper end of its 52-week range.

Second quarter growth reaches 9.6 percent

In its account of the August 5, 2026 results, Yahoo Finance reported net operating revenue of USD 1.597 billion, up 9.6 percent from the prior-year quarter. Adjusted EPS rose 10.7 percent to USD 1.55, while patient discharges increased 5.6 percent to 68,895.

The operating mix matters because the growth came from both volume and pricing. Net patient revenue per discharge increased 3.9 percent to USD 22,521, according to Yahoo Finance, giving the company a measurable contribution from higher patient activity and revenue per case.

Guidance points to a larger 2026 base

The same results account said full-year 2026 guidance increased to USD 6.41 billion to USD 6.49 billion in net operating revenue, USD 1.365 billion to USD 1.395 billion in adjusted EBITDA and USD 6.02 to USD 6.25 in adjusted EPS. The ranges are higher than the company projections issued one quarter earlier, making guidance progression a central test for the next report.

Simply Wall St lists October 28, 2026, as the date for Encompass Health's third quarter 2026 results. That release should show whether the 5.6 percent discharge increase and the 3.9 percent revenue-per-discharge increase are continuing beyond the second quarter.

Analysts see further upside

According to MarketBeat on October 6, 2026, the consensus rating was Buy with an average price target of USD 148.50 from seven brokerages. That target lies 19.1 percent above the USD 124.69 price, while the stock's 52-week range was USD 92.77 to USD 127.99.

MarketBeat also reported that the stock moved above its 200-day moving average of USD 109.95 during October 6 trading. The technical level is secondary to the earnings trend, but it shows how the recent price move has carried the shares above a widely followed long-term average.

Encompass Health stock stays near its yearly high

Encompass Health stock was last at USD 124.69 on the NYSE on October 6, 2026, at 4:00 p.m. ET, with volume of 1,295,466 shares. Its market capitalization was USD 12.4 billion on the same date.